The impact of Gam-COVID-Vac, an Adv5/Adv26 COVID-19 vaccine, on the biomarkers of endothelial function, coagulation and platelet activation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
08
2023
accepted:
03
10
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
COVID-19 vaccines have played a critical role in controlling the COVID-19 pandemic. Although overall considered safe, COVID-19 vaccination has been associated with rare but severe thrombotic events, occurring mainly in the context of adenoviral vectored vaccines. A better understanding of mechanisms underlying vaccine-induced hypercoagulability and prothrombotic state is needed to improve vaccine safety profile. We assessed changes to the biomarkers of endothelial function (endothelin, ET-1), coagulation (thrombomodulin, THBD and plasminogen activator inhibitor, PAI) and platelet activation (platelet activating factor, PAF, and platelet factor 4 IgG antibody, PF4 IgG) within a three-week period after the first (prime) and second (boost) doses of Gam-Covid-Vac, an AdV5/AdV26-vectored COVID-19 vaccine. Blood plasma collected from vaccinees (n = 58) was assayed using ELISA assays. Participants were stratified by prior COVID-19 exposure based on their baseline SARS-CoV-2-specific serology results. We observed a significant post-prime increase in circulating ET-1, with levels sustained after the boost dose compared to baseline. ET-1 elevation following dose 2 was most pronounced in vaccinees without prior COVID-19 exposure. Prior COVID-19 was also associated with a mild increase in post-dose 1 PAI. Vaccination was associated with elevated ET-1 up to day 21 after the second vaccine dose, while no marked alterations to other biomarkers, including PF4 IgG, were seen. A role of persistent endothelial activation following COVID-19 vaccination warrants further investigation.
Identifiants
pubmed: 37851684
doi: 10.1371/journal.pone.0293074
pii: PONE-D-23-24803
pmc: PMC10584095
doi:
Substances chimiques
COVID-19 Vaccines
0
Biomarkers
0
Immunoglobulin G
0
Platelet Factor 4
37270-94-3
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293074Informations de copyright
Copyright: © 2023 Turmukhambetova et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2022 Oct 13;387(15):1431-1432
pubmed: 36103622
Front Cardiovasc Med. 2022 Sep 29;9:967926
pubmed: 36247442
Sci Rep. 2022 May 13;12(1):7961
pubmed: 35562373
Lancet Reg Health Eur. 2021 May;4:100096
pubmed: 33880458
Front Immunol. 2021 Nov 23;12:779453
pubmed: 34887867
J Mol Cell Cardiol. 2022 Jun;167:92-96
pubmed: 35339512
Immunother Adv. 2021 Aug 17;1(1):ltab019
pubmed: 34557868
Nat Rev Cardiol. 2022 Jul;19(7):475-495
pubmed: 35027697
Thromb Res. 2022 Jan;209:106-114
pubmed: 34922160
ESC Heart Fail. 2022 Apr;9(2):1483-1486
pubmed: 35106967
Br J Haematol. 2022 Jul;198(2):257-266
pubmed: 35577507
Thromb Res. 2023 Mar;223:24-33
pubmed: 36702064
Blood. 2007 Apr 1;109(7):2832-9
pubmed: 17148587
Sci Rep. 2022 Aug 1;12(1):13207
pubmed: 35915123
Front Cardiovasc Med. 2022 Jul 29;9:966028
pubmed: 35966540
PLoS One. 2022 Jul 27;17(7):e0272008
pubmed: 35895743
Front Public Health. 2023 Jun 07;11:1205159
pubmed: 37351091